Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After th...
With the advent of new-age healthcare industry trends that are evident as of now, there...
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...
The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...
Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...
There has been limited progress in the approval of novel agents in MDS. It has been a l...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
